Plus Therapeutics to Current on the Gordon Analysis Convention Radionuclide Theranostics for the Administration of Most cancers

AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Firm”), a clinical-stage pharmaceutical firm growing focused radiotherapeutics with superior platform applied sciences for central nervous system (CNS) cancers, at the moment introduced that Melissa Moore, Ph.D., Vice President, Scientific Analysis and Growth, will give a presentation at 11:30 a.m. EDT on the Gordon Analysis Convention Radionuclide Theranostics for the Administration of Most cancers on July 8, 2024 in Newry, Maine.

The presentation will report information from the ReSPECT-GBM and ReSPECT-LM scientific research evaluating the Firm’s lead radiotherapeutic, rhenium (¹⁸⁶Re) obisbemeda, for the remedy of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).

Particulars of shows:

About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical firm growing focused radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to reinforce scientific outcomes for sufferers. Combining image-guided native beta radiation and focused drug supply approaches, the Firm is advancing a pipeline of product candidates with lead packages in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Firm has constructed a provide chain by strategic partnerships that allow the event, manufacturing, and future potential commercialization of its merchandise. Plus Therapeutics is led by an skilled and devoted management crew and has operations in key most cancers scientific improvement hubs together with Austin and San Antonio, Texas. For extra info, go to https://plustherapeutics.com/.

Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Workplace: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com